Applied Biosystems/MDS Analytical Technologies Launches Mass Spectrometer for Proteomics Research
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Applied Biosystems and its mass spectrometry joint-venture partner, MDS Analytical Technologies have introduced the AB SCIEX TOF/TOF™ 5800 System, most sensitive MALDI-based mass spectrometer ever built. This system, which is now commercially available, will help researchers advance the discovery of biomarkers to improve the understanding of diseases for potential use in a clinical setting, which is part of the promise of personalized medicine.
The AB SCIEX 5800 System represents an advancement in MALDI-TOF mass spectrometry (matrix-assisted laser desorption/ionization time-of-flight technology), which works by ionizing complex biological samples and identifying the individual protein components by their molecular weight.
According to both the companies, this system is designed to enable researchers to identify up to 30% more proteins at a rate that is 10 times faster than any other MALDI system on the market, thereby setting the highest standard for protein biomarker discovery, MALDI imaging and protein identification. This system, combined with the release of a new processing software application, ProteinPilot™ 3.0, is part of a complete workflow that accelerates proteomics research.
By expanding the boundaries of protein discovery, the AB SCIEX 5800 System enables scientists to achieve in less than a day what takes more than two weeks on other MALDI-based systems. This system is expected to advance the discovery of new biomarkers that could potentially yield clinical tests in the future, which is a high priority in the medical and scientific communities.
The AB SCIEX 5800 System enables the discovery of a wider range of protein biomarkers, enabling scientists to identify and quantify more proteins in complex samples.
Laura Lauman, President of Life Technologies Mass Spectrometry Systems Division, said, “The ability to better understand diseases at the protein level will ultimately improve diagnosis and help to create more effective treatments based on an individual’s expression of specific proteins that relate to a disease or a response to targeted therapies. The AB SCIEX 5800 System delivers innovative, breakthrough technology that provides a giant technological leap forward that will help translate today's biomarker research into tomorrow's personalized medicine.”
The AB SCIEX 5800 System represents an advancement in MALDI-TOF mass spectrometry (matrix-assisted laser desorption/ionization time-of-flight technology), which works by ionizing complex biological samples and identifying the individual protein components by their molecular weight.
According to both the companies, this system is designed to enable researchers to identify up to 30% more proteins at a rate that is 10 times faster than any other MALDI system on the market, thereby setting the highest standard for protein biomarker discovery, MALDI imaging and protein identification. This system, combined with the release of a new processing software application, ProteinPilot™ 3.0, is part of a complete workflow that accelerates proteomics research.
By expanding the boundaries of protein discovery, the AB SCIEX 5800 System enables scientists to achieve in less than a day what takes more than two weeks on other MALDI-based systems. This system is expected to advance the discovery of new biomarkers that could potentially yield clinical tests in the future, which is a high priority in the medical and scientific communities.
The AB SCIEX 5800 System enables the discovery of a wider range of protein biomarkers, enabling scientists to identify and quantify more proteins in complex samples.
Laura Lauman, President of Life Technologies Mass Spectrometry Systems Division, said, “The ability to better understand diseases at the protein level will ultimately improve diagnosis and help to create more effective treatments based on an individual’s expression of specific proteins that relate to a disease or a response to targeted therapies. The AB SCIEX 5800 System delivers innovative, breakthrough technology that provides a giant technological leap forward that will help translate today's biomarker research into tomorrow's personalized medicine.”
